InvestorsHub Logo
Followers 16
Posts 1775
Boards Moderated 0
Alias Born 08/05/2008

Re: None

Tuesday, 12/05/2017 7:43:09 AM

Tuesday, December 05, 2017 7:43:09 AM

Post# of 7185
Revance's RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines
http://investors.revance.com/releasedetail.cfm?ReleaseID=1050685

- Highly statistically significant results on primary composite endpoint achieved at Week 4 -
- RT002 delivered highly statistically significant reduction in severity of glabellar lines at Week 24 -
- If approved, RT002 could represent a new, next-generation, long-acting neuromodulator -
- Revance to host conference call at 8:00 am ET today -
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News